157664-97-6

Upstream product

• 931-15-7 (1S,2S)-trans-2-aminocyclohexanol 
• 98-88-4 benzoyl chloride 
• 98361-56-9 (1S,2S)-trans-2-[(R)-(α-methylbenzyl)amino]cyclohexanol 
• 286-20-4 cyclohexane-1,2-epoxide 
• 322407-55-6 (1S,2S)-trans-2-(N,O-dibenzoyl)aminocyclohexanol 

Downstream Products

• 322407-34-1 (1S,2S)-trans-2-(N-benzyl)amino-1-cyclohexanol 
• 322407-35-2 (1S,2S)-trans-2-(N-benzenesulfonyl)aminocyclohexanol 
• 322407-58-9 (1S,2S)-trans-2-(N-benzenesulfonyl-N-benzyl)aminocyclohexyl bromoacetate 
• 322407-41-0 (1S,2S)-trans-2-(N-benzenesulfonyl-N-benzyl)aminocyclohexyl (triphenylphosphoranylidene)acetate 

Relevant academic research and scientific papers

Application of new chiral auxiliaries, trans-2-(N-arylsulfonyl-N-benzyl)cyclohexanols, in an asymmetric radical cyclization

New chiral auxiliaries, trans-2-(N-arylsulfonyl-N-benzyl)cyclohexanols, were prepared and applied to an asymmetric radical cyclization. Copyright (C) 2000 Elsevier Science Ltd.

NITROGEN-CONTAINING CYCLOHETERO CYCLOALKYLAMINOARYL DERIVATIVES FOR CNS DISORDERS

Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders, convulsions and parkinsonism. Compounds of particular interest are of the formula STR1 wherein R 1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms and loweralkenylloweralkyl; wherein each of R 2 and R 3 is independently selected from hydrido and loweralkyl; wherein each of R 4 through R 7, R 10 and R 11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is a number selected from four through six; wherein p is a number selected from zero through four; wherein q is a number selected from three through five; wherein A is selected from phenyl, naphthyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.

Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS disorders

Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders and convulsions. Compounds of particular interest are of the formula STR1 wherein R1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms, and loweralkenylloweralkyl; wherein each of R2 and R3 is independently selected from hydrido and loweralkyl; wherein each of R4 through R7, R10 and R11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is a number selected from four through six; wherein p is a number selected from zero through four; wherein q is a number selected from three through five; wherein A is selected from phenyl, naphthyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.